Factor This Power Engineering
Live Events
DTECH⢠Events
POWERGEN®
Calendar
Resource Center
Webinars
Podcasts
White Papers
Contribute Content
Solar
Utility Scale
Community
Residential
Wind Power
Turbines & Equipment
Offshore
Power Grid
Transmission
Outage Management
Grid Modernization
Smart Grids
Microgrids
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Pumped Storage
Long Duration
Business
Policy & Regulation
Project Development
Finance
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Utility Scale
Community
Residential
Wind Power
Turbines & Equipment
Offshore
Power Grid
Transmission
Outage Management
Grid Modernization
Smart Grids
Microgrids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Pumped Storage
Long Duration
Business
Policy & Regulation
Finance
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Resource Center
Webinars
Podcasts
Whitepapers
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Xenon Pharmaceuticals Inc. - Common Shares
(NQ:
XENE
)
61.88
+19.94 (+47.53%)
Streaming Delayed Price
Updated: 3:47 PM EDT, Mar 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Xenon Pharmaceuticals Inc. - Common Shares
< Previous
1
2
3
4
Next >
Xenon Pharmaceuticals Announces Proposed Public Offering
Today 16:01 EDT
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)
Today 7:00 EDT
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026
March 08, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
February 26, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
January 12, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
December 05, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025
December 03, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025
November 25, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Present at Upcoming Investor Conferences
November 06, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Reports Third Quarter 2025 Financial Results & Business Update
November 03, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Report Q3 2025 Financial Results on November 3, 2025
October 27, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer
October 16, 2025
Mr. Kelly is a proven strategic CFO with significant financial, operational and commercialization leadership experience
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 07, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain
September 25, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Design Therapeutics Appoints Justin Gover to Board of Directors
September 10, 2025
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 29, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Reports Second Quarter 2025 Financial Results & Business Update
August 11, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Report Q2 2025 Financial Results on August 11, 2025
August 04, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Joins the Russell 3000® and Russell 2000® Indexes
June 27, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 26, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Announces Appointment of Darren Cline as Chief Commercial Officer
June 24, 2025
Mr. Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage company with the anticipated launch of azetukalner across three potential indications
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
June 03, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 30, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference
May 14, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Reports First Quarter 2025 Financial Results and Provides Business Update
May 12, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Report Q1 2025 Financial Results on May 12, 2025
May 05, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
